Physician profile
Sofia Shapiro
NPI 1265581714
$4,557.99
in general payments reported to CMS, 2019-2025
40 companies · $769 in 2025
The $769 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $352 · 2021: $477 · 2022: $614 · 2023: $821 · 2024: $952 · 2025: $769.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.31 |
| Education | $142.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,128.85 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $384.62 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $277.63 | 2021-2024 | Vraylar |
| Calliditas Therapeutics US INC. | $242.36 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $240.11 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $213.89 | 2022-2025 | |
| Pfizer INC. | $168.72 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $148.19 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $131.11 | 2023 | Rayaldee |
| Merck Sharp & Dohme LLC | $129.07 | 2019-2025 | Gardasil 9, Capvaxive, Pneumovax 23 |
| Astrazeneca Pharmaceuticals Lp | $121.93 | 2020-2024 | Lokelma, Farxiga, Breztri |
| Vifor Pharma, INC. | $113.75 | 2021-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $108.17 | 2023-2025 | Jynarque |
| Boston Scientific Corporation | $94.49 | 2019 | |
| Mallinckrodt Hospital Products INC. | $94.29 | 2022-2025 | Acthar |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $92.87 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $83.84 | 2023-2024 | Edarbyclor, Edarbi |
| Alfasigma USA, INC. | $78.98 | 2021-2022 | |
| Lilly USA, LLC | $63.32 | 2019-2024 | Zepbound |
| Exact Sciences Corporation | $61.72 | 2023-2025 | Cologuard Collection Kit |
| Theratechnologies INC. | $56.18 | 2019 | |
| Travere Therapeutics, INC. | $49.08 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $46.29 | 2023-2024 | Purified Cortrophin Gel |
| Arbor Pharmaceuticals, INC. | $44.69 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $44.04 | 2019 | |
| Viiv Healthcare Company | $43.21 | 2019-2020 | |
| Renalytix Ai, INC. | $39.65 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Teva Pharmaceuticals USA, INC. | $39.23 | 2019-2020 | |
| Janssen Biotech, INC. | $29.93 | 2019 | |
| Global Blood Therapeutics, INC. | $26.15 | 2022 | |
| Astellas Pharma US INC | $21.86 | 2025 | Veozah |
| Phadia US INC. | $17.61 | 2024 | Immunocap |
| Regeneron Healthcare Solutions, INC. | $17.14 | 2019 | |
| Glaxosmithkline, LLC. | $17.00 | 2024 | Arexvy |
| Genentech USA, INC. | $15.00 | 2019 | |
| Esperion Therapeutics, INC. | $14.91 | 2025 | Nexletol |
| Zealand Pharma US, INC. | $14.74 | 2021 | |
| Nabriva Therapeutics, Plc | $14.74 | 2020 | |
| Aurinia Pharma U.S., INC. | $14.65 | 2024 | Lupkynis |
| Cequr Corporation | $13.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sofia Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.